374 related articles for article (PubMed ID: 17474358)
21. Treatment of cutaneous T-cell lymphoma.
Zackheim HS
Semin Dermatol; 1994 Sep; 13(3):207-15. PubMed ID: 7986690
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic approaches in cutaneous lymphoma.
Jörg B; Kerl H; Thiers BH; Bröcker EB; Burg G
Dermatol Clin; 1994 Apr; 12(2):433-41. PubMed ID: 8045054
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
24. An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.
Geskin L; Malone DC
J Dermatolog Treat; 2018 Aug; 29(5):522-530. PubMed ID: 29191068
[TBL] [Abstract][Full Text] [Related]
25. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
26. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
27. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
[TBL] [Abstract][Full Text] [Related]
28. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
Talpur R; Duvic M
Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
[TBL] [Abstract][Full Text] [Related]
29. Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.
Kerl K; Prins C; Cerroni L; French LE
Br J Dermatol; 2006 May; 154(5):988-91. PubMed ID: 16634908
[TBL] [Abstract][Full Text] [Related]
30. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.
Rook AH; Junkins-Hopkins JM; McGinnis KS; Wysocka M; Richardson SK; Budgin JB; Everitts S; Vittorio CC
Adv Dermatol; 2002; 18():29-43. PubMed ID: 12528401
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal Antibodies.
Geskin LJ
Dermatol Clin; 2015 Oct; 33(4):777-86. PubMed ID: 26433849
[TBL] [Abstract][Full Text] [Related]
33. Treatment of cutaneous T-cell lymphoma/mycosis fungoides.
Parker SR; Bradley B
Dermatol Nurs; 2006 Dec; 18(6):566-70, 573-5. PubMed ID: 17286158
[TBL] [Abstract][Full Text] [Related]
34. Forodesine in the treatment of cutaneous T-cell lymphoma.
Lewis DJ; Duvic M
Expert Opin Investig Drugs; 2017 Jun; 26(6):771-775. PubMed ID: 28447489
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous T cell lymphoma: update of treatment.
Zackheim HS
Dermatology; 1999; 199(2):102-5. PubMed ID: 10559573
[TBL] [Abstract][Full Text] [Related]
36. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
Wobser M; Göppner D; Lang SC; Beckmann G; Flentje M; Ugurel S; Bröcker EB; Becker JC
Arch Dermatol; 2010 Jul; 146(7):805-6. PubMed ID: 20644054
[No Abstract] [Full Text] [Related]
37. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
38. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Duvic M
Hematology Am Soc Hematol Educ Program; 2015; 2015():529-44. PubMed ID: 26637769
[No Abstract] [Full Text] [Related]
39. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous T-cell lymphoma. New immunomodulators.
Apisarnthanarax N; Duvic M
Dermatol Clin; 2001 Oct; 19(4):737-48. PubMed ID: 11705358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]